Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Detrusor, Overactive Clear all
Completed Phase 3 Interventional Results available

A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity

NCT01852058
View directory record Official record
Conditions
Urinary Incontinence
Interventions
OnabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 24, 2026, 8:24 AM EDT
Terminated Phase 3 Interventional Results available

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

NCT02660138
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 24, 2026, 8:24 AM EDT
Terminated Phase 3 Interventional Results available

Over Active Bladder Instillation Study - Botox

NCT00667095
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Urge Incontinence
Interventions
Botox Instillation, DMSO Instillation
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 24, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Results available

Minimizing Pain During Office Intradetrussor Botox Injection

NCT04270526
View directory record Official record
Conditions
Overactive Bladder, Overactive Detrusor, Overactive Bladder Syndrome, Overactivity; Behavior, Urge Incontinence
Interventions
Bicarbonate protocol, Standard protocol
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 24, 2026, 8:24 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Device for Bladder Control for Men With SCI

NCT07668063
View directory record Official record
Conditions
Neurogenic Bladder
Interventions
Noninvasive electrical stimulation device to improve bladder control
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 24, 2026, 8:24 AM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 24, 2026, 8:24 AM EDT
Recruiting No phase listed Observational

Noninvasive Ultrasound Assessment of Detrusor Dysfunction

NCT05652023
View directory record Official record
Conditions
Bladder Dysfunction, Overactive Bladder, BPH With Urinary Obstruction
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
2,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 24, 2026, 8:24 AM EDT
Not listed Phase 2 Interventional

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury

NCT03187795
View directory record Official record
Conditions
Spinal Cord Injuries, Urinary Bladder, Neurogenic
Interventions
Oxybutynin Chloride IR, Mirabegron
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 24, 2026, 8:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation

NCT01850706
View directory record Official record
Conditions
Detrusor Overactivity
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 24, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Results available

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

NCT01093534
View directory record Official record
Conditions
Detrusor Overactivity, Overactive Bladder
Interventions
Placebo, solifenacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
New York, New York • West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 24, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

NCT00224029
View directory record Official record
Conditions
Detrusor Hyperreflexia
Interventions
Oxybutynin transdermal system
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Atlanta, Georgia • The Bronx, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2010 · Synced Sep 24, 2026, 8:24 AM EDT
Recruiting Not applicable Interventional

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women

NCT07209397
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant), Mixed Urinary Incontinence, Idiopathic Overactive Bladder With Urinary Incontinence, Idiopathic Overactive Bladder
Interventions
Detrusor nerve radiofrequency ablation, Simulated (sham) detrusor nerve radiofrequency ablation
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
22 Years to 80 Years · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 24, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years

NCT00857896
View directory record Official record
Conditions
Overactive Bladder, Neurogenic Detrusor Overactivity
Interventions
Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
8 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Little Rock, Arkansas • Long Beach, California • Overland Park, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Sep 24, 2026, 8:24 AM EDT
Recruiting Phase 2Phase 3 Interventional

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

NCT05878951
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 24, 2026, 8:24 AM EDT
Recruiting Phase 2Phase 3 Interventional

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

NCT05491525
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 24, 2026, 8:24 AM EDT
Not listed Phase 4 Interventional

Oral vs Intravesical Analgesia for Office Bladder Botox Injections

NCT03755089
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Detrusor Instability
Interventions
Phenazopyridine, Lidocaine 2% Injectable Solution
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Sep 24, 2026, 8:24 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

NCT00495053
View directory record Official record
Conditions
Overactive Bladder
Interventions
hMaxi-K, Placebo
Drug · Other
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Branford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 24, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

NCT01852045
View directory record Official record
Conditions
Urinary Incontinence
Interventions
OnabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 24, 2026, 8:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Botulin-A Toxin Instillations and Overactive Bladder

NCT00583219
View directory record Official record
Conditions
Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia
Interventions
Botulinum-A toxin, Dimethyl sulfoxide (DMSO)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 24, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia

NCT00605319
View directory record Official record
Conditions
Bladder Outlet Obstruction
Interventions
Toviaz (Fesoterodine)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 99 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 24, 2026, 8:24 AM EDT